TrialArthritis & rheumatology (Hoboken, N.J.)2015

A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.

J Sieper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.